BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Tamhane S, Rodriguez-Gutierrez R, Iqbal AM, Prokop LJ, Bancos I, Speiser PW, Murad MH. Cardiovascular and Metabolic Outcomes in Congenital Adrenal Hyperplasia: A Systematic Review and Meta-Analysis. J Clin Endocrinol Metab 2018;103:4097-103. [PMID: 30272185 DOI: 10.1210/jc.2018-01862] [Cited by in Crossref: 22] [Cited by in F6Publishing: 22] [Article Influence: 7.3] [Reference Citation Analysis]
Number Citing Articles
1 Borges JH, Santoro RI, de Oliveira DM, de Lemos-Marini SHV, Geloneze B, Guerra-Júnior G, Gonçalves EM. Cardiovascular dysfunction risk in young adults with congenital adrenal hyperplasia caused by 21-hydroxylase enzyme deficiency. Int J Clin Pract 2021;75:e14233. [PMID: 33884716 DOI: 10.1111/ijcp.14233] [Reference Citation Analysis]
2 Al Alawi AM, Nordenström A, Falhammar H. Clinical perspectives in congenital adrenal hyperplasia due to 3β-hydroxysteroid dehydrogenase type 2 deficiency. Endocrine 2019;63:407-21. [PMID: 30719691 DOI: 10.1007/s12020-018-01835-3] [Cited by in Crossref: 25] [Cited by in F6Publishing: 19] [Article Influence: 8.3] [Reference Citation Analysis]
3 Torky A, Sinaii N, Jha S, Desai J, El-Maouche D, Mallappa A, Merke DP. Cardiovascular Disease Risk Factors and Metabolic Morbidity in a Longitudinal Study of Congenital Adrenal Hyperplasia. J Clin Endocrinol Metab 2021;106:e5247-57. [PMID: 33677504 DOI: 10.1210/clinem/dgab133] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
4 Merke DP, Mallappa A, Arlt W, Brac de la Perriere A, Lindén Hirschberg A, Juul A, Newell-Price J, Perry CG, Prete A, Rees DA, Reisch N, Stikkelbroeck N, Touraine P, Maltby K, Treasure FP, Porter J, Ross RJ. Modified-Release Hydrocortisone in Congenital Adrenal Hyperplasia. J Clin Endocrinol Metab 2021;106:e2063-77. [PMID: 33527139 DOI: 10.1210/clinem/dgab051] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
5 Elfekih H, Abdelkrim AB, Marzouk H, Saad G, Gribaa M, Hasni Y, Maaroufi A. Congenital adrenal hyperplasia due to 11-Beta-hydroxylase deficiency in a Tunisian family. Pan Afr Med J 2020;36:226. [PMID: 33708317 DOI: 10.11604/pamj.2020.36.226.24270] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
6 Vijayan R, Bhavani N, Pavithran PV, Nair V, Menon UV, Menon AS, Abraham N, Bhadran K, Narayanan P, Kumar H. Metabolic profile, cardiovascular risk factors and health-related quality of life in children, adolescents and young adults with congenital adrenal hyperplasia. Journal of Pediatric Endocrinology and Metabolism 2019;32:871-7. [DOI: 10.1515/jpem-2019-0079] [Cited by in Crossref: 7] [Cited by in F6Publishing: 6] [Article Influence: 2.3] [Reference Citation Analysis]
7 Hashemi Dehkordi E, Khaheshi S, Mostofizadeh N, Hashemipour M. Cardiovascular Risk Factors in Children and Adolescents with Congenital Adrenal Hyperplasia. Adv Biomed Res 2021;10:19. [PMID: 34476227 DOI: 10.4103/abr.abr_219_20] [Reference Citation Analysis]
8 Delai A, Gomes PM, Foss-Freitas MC, Elias J, Antonini SR, Castro M, Moreira AC, Mermejo LM. Hyperinsulinemic-euglycaemic clamp strengthens the insulin resistance in nonclassical congenital adrenal hyperplasia. J Clin Endocrinol Metab 2021:dgab767. [PMID: 34693966 DOI: 10.1210/clinem/dgab767] [Reference Citation Analysis]
9 Rosenberg AGW, Pater MRA, Pellikaan K, Davidse K, Kattentidt-Mouravieva AA, Kersseboom R, Bos-Roubos AG, van Eeghen A, Veen JMC, van der Meulen JJ, van Aalst-van Wieringen N, Hoekstra FME, van der Lely AJ, de Graaff LCG. What Every Internist-Endocrinologist Should Know about Rare Genetic Syndromes in Order to Prevent Needless Diagnostics, Missed Diagnoses and Medical Complications: Five Years of 'Internal Medicine for Rare Genetic Syndromes'. J Clin Med 2021;10:5457. [PMID: 34830739 DOI: 10.3390/jcm10225457] [Reference Citation Analysis]
10 Puttabyatappa M, Sargis RM, Padmanabhan V. Developmental programming of insulin resistance: are androgens the culprits? J Endocrinol 2020;245:R23-48. [PMID: 32240982 DOI: 10.1530/JOE-20-0044] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 5.0] [Reference Citation Analysis]
11 Ahmed SEAM, Soliman AT, Ramadan MA, Elawwa A, Abugabal AMS, Emam MHA, De Sanctis V. Long-term prednisone versus hydrocortisone treatment in children with classic Congenital Adrenal Hyperplasia (CAH) and a brief review of the literature. Acta Biomed 2019;90:360-9. [PMID: 31580328 DOI: 10.23750/abm.v90i3.8732] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
12 Gomes LG, Mendonca BB, Bachega TASS. Long-term cardio-metabolic outcomes in patients with classical congenital adrenal hyperplasia: is the risk real? Curr Opin Endocrinol Diabetes Obes 2020;27:155-61. [PMID: 32304389 DOI: 10.1097/MED.0000000000000545] [Cited by in Crossref: 8] [Cited by in F6Publishing: 1] [Article Influence: 4.0] [Reference Citation Analysis]
13 Improda N, Barbieri F, Ciccarelli GP, Capalbo D, Salerno M. Cardiovascular Health in Children and Adolescents With Congenital Adrenal Hyperplasia Due to 21-Hydroxilase Deficiency. Front Endocrinol (Lausanne) 2019;10:212. [PMID: 31031703 DOI: 10.3389/fendo.2019.00212] [Cited by in Crossref: 6] [Cited by in F6Publishing: 3] [Article Influence: 2.0] [Reference Citation Analysis]
14 Borges JH, de Oliveira DM, de Lemos-Marini SHV, Geloneze B, Gonçalves EM, Guerra-Júnior G. Fat Distribution and Lipid Profile of Young Adults with Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Enzyme Deficiency. Lipids 2021;56:101-10. [PMID: 32929736 DOI: 10.1002/lipd.12280] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
15 Kim MS, Fraga NR, Minaeian N, Geffner ME. Components of Metabolic Syndrome in Youth With Classical Congenital Adrenal Hyperplasia. Front Endocrinol 2022;13:848274. [DOI: 10.3389/fendo.2022.848274] [Reference Citation Analysis]
16 Kocova M, Concolino P, Falhammar H. Characteristics of In2G Variant in Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency. Front Endocrinol 2022;12:788812. [DOI: 10.3389/fendo.2021.788812] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
17 Mallappa A, Merke DP. Management challenges and therapeutic advances in congenital adrenal hyperplasia. Nat Rev Endocrinol. [DOI: 10.1038/s41574-022-00655-w] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
18 Takasawa K, Kashimada K. Toward Improving the Transition of Patients With Congenital Adrenal Hyperplasia From Pediatrics to Adult Healthcare in Japan. Front Pediatr 2022;10:936944. [DOI: 10.3389/fped.2022.936944] [Reference Citation Analysis]
19 Nordenström A, Lajic S, Falhammar H. Clinical outcomes in 21-hydroxylase deficiency. Curr Opin Endocrinol Diabetes Obes 2021;28:318-24. [PMID: 33741777 DOI: 10.1097/MED.0000000000000625] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 2.0] [Reference Citation Analysis]
20 Barbot M, Mazzeo P, Lazzara M, Ceccato F, Scaroni C. Metabolic syndrome and cardiovascular morbidity in patients with congenital adrenal hyperplasia. Front Endocrinol 2022;13:934675. [DOI: 10.3389/fendo.2022.934675] [Reference Citation Analysis]
21 Amr NH, Mahmoud RAA, Youssef O, Toaima NN, Elsedfy H. Effect of long-term glucocorticoid therapy on cardiac functions in children with congenital adrenal hyperplasia. Clin Endocrinol (Oxf) 2021;94:210-8. [PMID: 32946608 DOI: 10.1111/cen.14333] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
22 Banker M, Puttabyatappa M, O'Day P, Goodrich JM, Kelley AS, Domino SE, Smith YR, Dolinoy DC, Song PXK, Auchus RJ, Padmanabhan V. Association of Maternal-Neonatal Steroids With Early Pregnancy Endocrine Disrupting Chemicals and Pregnancy Outcomes. J Clin Endocrinol Metab 2021;106:665-87. [PMID: 33280001 DOI: 10.1210/clinem/dgaa909] [Cited by in Crossref: 1] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
23 de Oliveira DM, Tura A, Vasques ACJ, Camilo DF, Lima MM, de Lemos-Marini SHV, Goncalves EM, Guerra-Junior G, Geloneze B. Insulin Resistance in Congenital Adrenal Hyperplasia is Compensated for by Reduced Insulin Clearance. J Clin Endocrinol Metab 2021;106:e1574-85. [PMID: 33421070 DOI: 10.1210/clinem/dgab010] [Reference Citation Analysis]
24 Speiser PW, Arlt W, Auchus RJ, Baskin LS, Conway GS, Merke DP, Meyer-Bahlburg HFL, Miller WL, Murad MH, Oberfield SE, White PC. Congenital Adrenal Hyperplasia Due to Steroid 21-Hydroxylase Deficiency: An Endocrine Society Clinical Practice Guideline. J Clin Endocrinol Metab 2018;103:4043-88. [PMID: 30272171 DOI: 10.1210/jc.2018-01865] [Cited by in Crossref: 272] [Cited by in F6Publishing: 224] [Article Influence: 90.7] [Reference Citation Analysis]
25 de Vries L, Lebenthal Y, Phillip M, Shalitin S, Tenenbaum A, Bello R. Obesity and Cardiometabolic Risk Factors in Children and Young Adults With Non-classical 21-Hydroxylase Deficiency. Front Endocrinol (Lausanne) 2019;10:698. [PMID: 31681171 DOI: 10.3389/fendo.2019.00698] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
26 van der Sluis RJ, Hoekstra M. Glucocorticoids are active players and therapeutic targets in atherosclerotic cardiovascular disease. Mol Cell Endocrinol 2020;504:110728. [PMID: 31968221 DOI: 10.1016/j.mce.2020.110728] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 3.0] [Reference Citation Analysis]
27 Paizoni L, Auer MK, Schmidt H, Hübner A, Bidlingmaier M, Reisch N. Effect of androgen excess and glucocorticoid exposure on metabolic risk profiles in patients with congenital adrenal hyperplasia due to 21-hydroxylase deficiency. J Steroid Biochem Mol Biol 2020;197:105540. [PMID: 31730799 DOI: 10.1016/j.jsbmb.2019.105540] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 2.7] [Reference Citation Analysis]
28 Lim SG, Lee YA, Jang HN, Kong SH, Ahn CH, Kim SW, Shin CH, Kim JH. Long-Term Health Outcomes of Korean Adults With Classic Congenital Adrenal Hyperplasia Due to 21-Hydroxylase Deficiency. Front Endocrinol (Lausanne) 2021;12:761258. [PMID: 34712205 DOI: 10.3389/fendo.2021.761258] [Reference Citation Analysis]
29 Lee DH, Kong SH, Jang HN, Ahn CH, Lim SG, Lee YA, Kim SW, Kim JH. Association of androgen excess and bone mineral density in women with classical congenital adrenal hyperplasia with 21-hydroxylase deficiency. Arch Osteoporos 2022;17:45. [PMID: 35258698 DOI: 10.1007/s11657-022-01090-0] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
30 Grzęda E, Matuszewska J, Ziarniak K, Gertig-kolasa A, Krzyśko- Pieczka I, Skowrońska B, Sliwowska JH. Animal Foetal Models of Obesity and Diabetes – From Laboratory to Clinical Settings. Front Endocrinol 2022;13:785674. [DOI: 10.3389/fendo.2022.785674] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
31 Yoon JY, Cheon CK. Genotype and clinical outcomes in children with congenital adrenal hyperplasia. Pediatr Int 2021;63:658-63. [PMID: 32965796 DOI: 10.1111/ped.14478] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
32 de Vries L, Baum M, Horovitz M, Phillip M, Barash G, Pinhas-Hamiel O, Lazar L. Management of Fully Pubertal Girls With Nonclassical Congenital Adrenal Hyperplasia: Glucocorticoids Versus Oral Contraceptives. Endocr Pract 2021:S1530-891X(21)01176-9. [PMID: 34438053 DOI: 10.1016/j.eprac.2021.08.005] [Reference Citation Analysis]
33 de Oliveira DM, Vasques ACJ, Gonçalves EM, de Lemos-Marini SHV, Guerra-Junior G, Geloneze B. ENERGY EXPENDITURE IN 21-HYDROXYLASE CONGENITAL ADRENAL HYPERPLASIA PATIENTS AND COMPARISON WITH PREDICTIVE EQUATIONS. Endocr Pract 2020;26:388-98. [PMID: 31859548 DOI: 10.4158/EP-2019-0390] [Reference Citation Analysis]